Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
Matching articles
Showing 85–96 of 124 articles · Check methods and identity
- Check methods and identity
What the Current US Bremelanotide Label Covers
PT-141 is a name used for bremelanotide, a cyclic peptide that activates melanocortin receptors. A defined prescription product, Vyleesi, is FDA approved for a specific condition. The October 2026 US prescribing information explains which people and circumstances were included in that indication.
PT-1411 source (2026)
- Check methods and identity
How Two Phase 3 Trials Measured Desire and Distress Separately
Bremelanotide, also called PT-141, is a melanocortin receptor agonist. Two older phase 3 studies directly tested the prescription candidate in premenopausal women with hypoactive sexual desire disorder. The 2026 label still summarizes these pivotal comparisons.
PT-1412 sources (2019, 2026)
- Check methods and identity
What the 2026 Bremelanotide Label Reports About Safety
PT-141 is also known as bremelanotide. The October 2026 US label for the approved product, Vyleesi, records safety findings from its clinical evaluation. Those findings apply to that specific drug product and the settings in which it was studied.
PT-1411 source (2026)
- Check methods and identity
What a three-sample retatrutide analysis showed about labeling
Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. The “GLP-3” wording is a catalog label. A 2026 Australian paper examined a different question from the clinical trials.
RETA GLP-32 sources (2026)
- Check methods and identity
What the first TRANSCEND diabetes trial measured
Retatrutide is an investigational peptide that acts at GIP, GLP-1 and glucagon receptors. The catalog’s “GLP-3” wording describes this entry rather than a receptor.
RETA GLP-32 sources (2026)
- Check methods and identity
What the lab would have to verify about a preparation with both molecules
Retatrutide is an investigational peptide with activity at GIP, GLP-1 and glucagon receptors. IGF-1 LR3 is an engineered insulin-like growth factor protein. Research about making each material provides background for asking how scientists would verify a preparation containing both.
RETA / IGF-1 LR33 sources (2023, 2026)
- Check methods and identity
What the Early Selank Comparisons Measured About Anxiety
Selank is a synthetic seven-amino-acid peptide modeled on a peptide called tuftsin. It has been investigated in anxiety research. The direct clinical comparisons described here are older: a search of recent indexed articles did not identify a newer original trial that answered the same question.
Selank2 sources (2008, 2014)
- Check methods and identity
What Brain Connectivity Imaging Can Tell Us About Selank
Selank is a synthetic peptide modeled on tuftsin. An older study investigated whether Selank or a different peptide, Semax, changed patterns on brain scans in healthy volunteers. Its measurements were about brain activity at rest.
Selank1 source (2020)
- Check methods and identity
Why a kidney trial measured body water as well as lean mass
Semaglutide acts at the GLP-1 receptor. IGF-1 LR3 is an altered, extended version of the growth-factor protein IGF-1. The 2026 SMART analysis studied semaglutide alone versus placebo and asked whether changes in body composition were related to kidney measurements.
SEMA / IGF-1 LR32 sources (2023, 2026)
- Check methods and identity
What separate Alzheimer’s studies measured for these two molecules
Semaglutide is a modified GLP-1 receptor agonist peptide. IGF-1 LR3 is an engineered growth-factor protein. Researchers have studied each in connection with Alzheimer’s disease in very different settings.
SEMA / IGF-1 LR33 sources (2024, 2026)
- Check methods and identity
What binding-protein measurements tell us about semaglutide
Semaglutide activates the GLP-1 receptor. IGF-1 LR3 is a modified insulin-like growth factor protein with altered binding properties. An older human study measured IGF-binding proteins during semaglutide treatment.
SEMA / IGF-1 LR32 sources (1992, 2025)
- Check methods and identity
What Semax Changed in Gene Measurements After Experimental Ischemia
Semax is a synthetic peptide based in part on a region of adrenocorticotropic hormone. Researchers have used it in animal studies to ask whether parts of the brain respond differently after temporary loss and restoration of blood flow.
Semax1 source (2024)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
